Efficacy of Favipiravir Against Severe Ebola Virus Disease

Status Completed

Clinical Trial Summary

The purpose of this study is to explore the therapeutic efficacy of Favipiravir, a broad-spectrum antiviral drug against severe cases of Ebola Virus Disease (EVD), which is the most difficult aspect for clinical management of EVD due to its high fatality rate.

Clinical Trial Description

This is a prospective, open-label, controlled phase 2 trial of Favipiravir among severe cases (cases with hemorrhage, severe dehydration, consciousness disorders, shock, and high blood viral load with Ct value below 20) of confirmed EVD patients in the capital area of Sierra Leone. Patients with 13 years of age or older would be assigned in an 1:1 randomised manner to receive WHO-recommended therapy (mainly symptomatic and supportive therapies, control group. WHO, World Health Organization.) or oral Favipiravir (1600 mg twice on the first day, followed by a twice-daily dose of 600 mg until negative blood viral load detection or death) plus WHO-recommended therapy (treatment group). The primary efficacy end point was case fatality rate.The secondary efficacy endpoint is blood (plasma)viral load. Optimal inclusion number is 240 cases (120 for each group), but considering the actual situation of pandemic area, the front line doctors have the right to reset the inclusion number, and modify the study protocol according to the actual situation in the front. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02662855
Study type	Interventional
Source	Beijing Institute of Pharmacology and Toxicology
Contact
Status	Completed
Phase	Phase 2
Start date	November 2014
Completion date	May 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00374309` - Experimental Vaccine for Prevention of Ebola Virus Infection	Phase 1
Completed	`NCT03098862` - PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response
Completed	`NCT02509494` - Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo	Phase 3
Recruiting	`NCT06093646` - Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda	N/A
Completed	`NCT02495246` - A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV	Phase 1
Completed	`NCT04906629` - INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees	Phase 1
Completed	`NCT05064956` - Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)	Phase 2
Completed	`NCT02267109` - Phase 1 Trial of Ebola Vaccine in Mali	Phase 1
Withdrawn	`NCT04268966` - An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola	Phase 2
Not yet recruiting	`NCT04822376` - Prophylaxis Vaccine Antibodies Ebola	Phase 2
Recruiting	`NCT02333578` - Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment	N/A
Active, not recruiting	`NCT04152486` - Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC	Phase 3
Terminated	`NCT04250168` - Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response
Completed	`NCT03161366` - Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine	Phase 3
Completed	`NCT03140774` - Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines
Suspended	`NCT03462004` - Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein	Phase 1
Active, not recruiting	`NCT02876328` - Partnership for Research on Ebola VACcinations	Phase 2
Not yet recruiting	`NCT06126822` - Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination With the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC	Phase 3
Not yet recruiting	`NCT05202288` - Pilot Study Evaluating the Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers	Phase 2
Completed	`NCT02658331` - Evaluation of the FilmArray BioThreat-E Test	N/A